Danaher Corporation $DHR is Rhenman & Partners Asset Management AB’s 10th Largest Position

Rhenman & Partners Asset Management AB lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 26.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 99,052 shares of the conglomerate’s stock after selling 35,400 shares during the period. Danaher makes up 2.1% of Rhenman & Partners Asset Management AB’s holdings, making the stock its 10th biggest position. Rhenman & Partners Asset Management AB’s holdings in Danaher were worth $22,675,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. JPL Wealth Management LLC purchased a new position in shares of Danaher during the third quarter worth $25,000. Elevated Capital Advisors LLC purchased a new position in shares of Danaher during the fourth quarter worth $26,000. WFA of San Diego LLC purchased a new position in shares of Danaher during the second quarter worth $26,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Danaher during the third quarter worth $27,000. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of Danaher during the fourth quarter worth $27,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Analysts Set New Price Targets

DHR has been the subject of several recent research reports. Wells Fargo & Company reduced their target price on shares of Danaher from $240.00 to $212.00 and set an “equal weight” rating for the company in a report on Wednesday, April 22nd. Citigroup initiated coverage on shares of Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price target on the stock. Robert W. Baird dropped their price target on shares of Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Piper Sandler initiated coverage on shares of Danaher in a research report on Thursday. They set a “neutral” rating and a $200.00 price target on the stock. Finally, The Goldman Sachs Group dropped their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $233.61.

Danaher Stock Down 0.5%

DHR stock opened at $179.95 on Friday. The firm has a market cap of $127.37 billion, a PE ratio of 34.81, a P/E/G ratio of 2.41 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The firm’s fifty day moving average is $180.93 and its 200 day moving average is $204.78. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80.

Danaher (NYSE:DHR) last announced its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the business earned $1.88 earnings per share. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. On average, research analysts forecast that Danaher Corporation will post 8.45 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s dividend payout ratio (DPR) is 30.95%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.